Autogenous activated lymphocytes were sequentially administered as an adjuvant antitumor therapy to 10 dogs with spontaneous malignant tumors in the Veterinary Teaching Hospital at Hokkaido University. Peripheral blood mononuclear cells from tumor-bearing dogs were proliferated and activated for 14 days in culture using anti-canine CD3 antibody and human recombinant IL-2. The cells obtained were reactivated using IL-2 and human recombinant IFN-α. After sequential administration of these activated lymphocytes, proportions of CD4
+cells and CD8
+cells were changed in the peripheral blood in all cases, while serum IFN-γ concentration increased in two cases. These results suggest the possibility of strengthening cell-mediated immunity. The general physical conditions of all 10 patients remained stable, and the patients were comfortable during the entire period of lymphocyte administration. This shows that the quality of life of these tumor-bearing dogs was maintained in a relatively favorable state, with no evidence of any adverse effects in response to the sequential infusion of activated lymphocytes. As an adjuvant antitumor therapy, activated lymphocyte therapy is therefore believed to be applicable to and effective for tumor-bearing animals whose immunity may be somewhat suppressed. This therapy may encourage cell-mediated immunity against tumor growth and distant metastasis.
View full abstract